DV
Dividend Vision

SION — Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. (SION)

Total return is -64.1% over the past 1.5 years, 94.3 points behind SPY at 30.2%. Its deepest 1-year drawdown was 91.2%.

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing medicines to treat cystic fibrosis, with multiple drug candidates in Phase 1 and Phase 2 trials targeting different mechanisms of the disease. The company does not currently have an established distribution history. This security appeals to investors seeking exposure to early-stage biotech development, though it carries the risks inherent to clinical-stage companies without approved products.

SION key facts

Asset type
Stock
Asset class
Equity
Inception date
02/06/2025
Distribution frequency
None
Last close
$6.46
Market cap
$291,671,136
Average volume
2868200.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.15